Developing an individualized treatment plan for patients with schizoaffective disorder: From pharmacotherapy to psychoeducation

Journal of Clinical Psychiatry

Volumn 71, Issue SUPPL. 2, 2010, Pages 14-19

  Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; LITHIUM; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; AGITATION; AKATHISIA; ANOREXIA; ANXIETY; ARTICLE; COGNITIVE DEFECT; DROWSINESS; DYSKINESIA; DYSPEPSIA; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; MAINTENANCE THERAPY; NERVOUSNESS; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SOMNOLENCE; TREATMENT PLANNING; TREMOR; VOMITING; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CAREGIVERS; COGNITION; COMORBIDITY; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL CLASSIFICATION OF DISEASES; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 78650752884     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.9096su1cc.03     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. The World Health Organization. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Geneva, Switzerland: The World Health Organization; 2007. http://apps.who.int/dassifications/ apps/icd/icd10online/. Accessed August 19, 2010.
3. Salvatore P, Baldessarini RJ, Tohen M, et al. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 firstepisode psychotic disorder patients. J Clin Psychiatry. 2009; 70(4): 458-466.
4. Salvatore P, Baldessarini RJ, Tohen M, et al. McLean-Harvard international first-episode project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients (published online ahead of print July 13, 2010). J Clin Psychiatry.
5. Kane JM. Strategies for making an accurate differential diagnosis of schizoaffective disorder. J Clin Psychiatry. 2010: 71 (suppl 2): 4-7.
6. Lipkovich IA, Deberdt W, Csernansky JG, et al. Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res. 2009; 170(2-3): 161-167.
7. Benabarre A, Vieta E, Colom F, et al. Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur Psychiatry. 2001; 16(3): 167-172.
8. Marneros A, Rohde A, Deister A. Factors influencing the long-term outcome of schizoaffective disorders. Psychopathology. 1993: 26(3-4): 215-224. (Pubitemid 23258805)
9. Tohen M, Waternaux CM, Tsuang MT, et al. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord. 1990; 19(2): 79-86.
10. Harrow M, Grossman LS, Herbener ES, et al. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000; 177(5): 421-426.
11. Kaneda Y, Jayathilak K, Meltzer HY Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function. Psychiatry Res. 2009; 169(2): 178-179.
12. Reichenberg A, Weiser M, Rabinowitz J, et al. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry. 2002; 159(12): 2027-2035.
13. Torrent C, Martínez-Aran A, Amann B, et al. Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. Acta Psychiatr Scand. 2007; 116(6): 453-460. (Pubitemid 350086147)
14. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010; 71(5): 587-598.
15. Keck PE Jr, Reeves KR, Harrigan EP; for the Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001; 21(1): 27-35.
16. Glick ID, Mankoski R, Eudicone JM, et al. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009; 115(1-2): 18-26.
17. Roy Chengappa K, Kupfer DJ, Parepally H, et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord. 2007; 9(6): 609-617.
18. Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy. Br J Psychiatry. 1999; 174(1): 15-22.
19. Janicak PG, Keck PE Jr, Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol. 2001; 21(4): 360-368.
20. Vieta E, Goikolea JM, Corbella B, et al, for the Group for the Study of Risperidone in Affective Disorders (GSRAD). Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry. 2001; 62(10): 818-825.
21. Kudla D, Lambert M, Domin S, et al. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry. 2007; 22(3): 195-202.
22. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009; 70(7): 990-996.
23. Perkins DO, Johnson JL, Hamer RM, et al, for the HGDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006; 83(1): 53-63.
24. Tay SE. Compliance therapy: an intervention to improve inpatients' attitudes toward treatment. J Psychosoc Nurs Ment Health Serv. 2007; 45(6): 29-37.
25. Benabarre A, Castro P, Sánchez-Moreno J, et al. Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder (in Spanish) Actas Esp Psiquiatr. 2009; 37(3): 143-147.
26. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010; 71(suppl 2): 20-26.
27. Sibitz I, Amering M, Gössler R, et al. One-year outcome of low-intensity booster sessions versus care as usual in psychosis patients after a short-term psychoeducational intervention. Eur Psychiatry. 2007; 22(4): 203-210. (Pubitemid 46727013)
28. Vreeland B, Minsky S, Yanos PT, et al. Efficacy of the team solutions program for educating patients about illness management and treatment. Psychiatr Serv. 2006; 57(6): 822-828.
29. Pitschel-Walz G, Bäuml J, Bender W, et al. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry. 2006; 67(3): 443-452.
30. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003; 60(4): 402-407.
31. Reinares M, Colom F, Sánchez-Moreno J, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord. 2008; 10(4): 511-519. (Pubitemid 351619167)
32. Byerly MJ, Fisher R, Carmody T, et al. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005; 66(8): 997-1001.
33. Granholm E, McQuaid JR, McClure FS, et al. Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. J Clin Psychiatry. 2007; 68(5): 730-737. (Pubitemid 46841856)
34. Patterson TL, Mausbach BT, McKibbin C, et al. Functional adaptation skills training (FAST): a randomized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders. Schizophr Res. 2006; 86(1-3): 291-299.
35. Lysaker PH, Bond G, Davis LW, et al. Enhanced cognitive-behavioral therapy for vocational rehabilitation in schizophrenia: Effects on hope and work. J Rehabil Res Dev. 2005; 42(5): 673-682.
36. Medda P, Perugi G, Zanello S, et al. Response to ECT in bipolar I, bipolar II and unipolar depression. J Affect Disord. 2009; 118(1-3): 55-59.
37. Swoboda E, Conca A, König P, et al. Maintenance electroconvulsive therapy in affective and schizoaffective disorder. Neuropsychobiology. 2001; 43(1): 23-28. (Pubitemid 32041418)